- Home
- SBFM vs RVPH Comparison
SBFM vs RVPH Comparison
Compare SBFM & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBFM | RVPH |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 71.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SBFM | RVPH |
|---|---|---|
| Price | $1.43 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $7.00 | $3.33 |
| AVG Volume (30 Days) | 66.6K | ★ 4.4M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,323,742.00 | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $32.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $1.17 | $0.25 |
| 52 Week High | $3.90 | $2.95 |
Technical Indicators
Market Signals| Indicator | SBFM | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 58.18 |
| Support Level | $1.43 | $0.60 |
| Resistance Level | $1.49 | $0.77 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 61.01 |
Price Performance
Historical ComparisonAbout SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.